<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02910323</url>
  </required_header>
  <id_info>
    <org_study_id>HSC-MS-15-0780</org_study_id>
    <nct_id>NCT02910323</nct_id>
  </id_info>
  <brief_title>The Will Erwin Headache Research Center - Cluster Headache Study</brief_title>
  <acronym>WEC1</acronym>
  <official_title>The Will Erwin Headache Research Center Study of Cluster Headache and Trigeminal Neuralgia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The University of Texas Health Science Center, Houston</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The University of Texas Health Science Center, Houston</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The Will Erwin Headache Research Center Study of Cluster Headache and Trigeminal Neuralgia is&#xD;
      a prospective, multicenter, observational research network for subjects with Cluster Headache&#xD;
      and/or Trigeminal Neuralgia.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The Will Erwin Headache Research Center will assemble a national registry of Cluster Headache&#xD;
      patients and will sub-categorize and organize this cohort based on individuating&#xD;
      characteristics including but not limited to type and severity of condition, associated&#xD;
      symptoms, and medical/psychological issues (e.g., depression, disability, sleep). Detailed&#xD;
      evaluations and classification will be completed for each enrolled subject. This will&#xD;
      encompass genomic and epigenomic studies, past medical history, imaging reports, and specific&#xD;
      physical exam results for each patient. It will also enable the study investigators to match&#xD;
      patients with suitable interventional clinical trials.&#xD;
&#xD;
      Similar diseases, such as other paroxysmal hemicrania, SUNCT, SUNA, hemicrania continua, and&#xD;
      trigeminal neuralgia may also be investigated.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>May 2016</start_date>
  <completion_date type="Anticipated">December 2035</completion_date>
  <primary_completion_date type="Anticipated">December 2035</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>HIT-6 scale</measure>
    <time_frame>Through study completion, an average of 5 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Morningness-eveningness scale</measure>
    <time_frame>Through study completion, an average of 5 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>GAD-7 scale</measure>
    <time_frame>Through study completion, an average of 5 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Genetic markers</measure>
    <time_frame>Through study completion, an average of 5 years</time_frame>
    <description>Results of GWAS or other genetic tests</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Molecular biomarkers</measure>
    <time_frame>Through study completion, an average of 5 years</time_frame>
    <description>Results of ELISAs for autonomic, hypothalamic, and pain signalling molecules</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">1500</enrollment>
  <condition>Cluster Headache</condition>
  <condition>Cluster Headaches and Other Trigeminal Autonomic Cephalgias</condition>
  <condition>Paroxysmal Hemicrania</condition>
  <condition>SUNCT</condition>
  <condition>Hemicrania Continua</condition>
  <condition>Trigeminal Neuralgia</condition>
  <arm_group>
    <arm_group_label>Experimental group</arm_group_label>
    <description>Patients with a history of Cluster Headaches and other TACs, or Trigeminal Neuralgia.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Family/Healthy Controls</arm_group_label>
    <description>Healthy volunteer controls and family members may be enrolled for identification of genetic mutations.</description>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood, urine, saliva, skin cells, other&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Cluster Headache and Trigeminal Neuralgia patients, family members and healthy volunteers&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Diagnosis of a trigeminal autonomic cephalalgia according to the International&#xD;
             Headache Classification including episodic cluster headache, chronic cluster headache,&#xD;
             episodic paroxysmal hemicrania, chronic paroxysmal hemicrania, episodic short-lasting&#xD;
             unilateral neuralgiform headache attacks with conjunctival injection and tearing&#xD;
             (SUNCT), chronic SUNCT, episodic short-lasting unilateral neuralgiform headache&#xD;
             attacks with cranial autonomic symptoms (SUNA), chronic SUNA, and hemicrania continua.&#xD;
             OR Diagnosis of a trigeminal neuralgia according to the International Headache&#xD;
             Classification, including classical trigeminal neuralgia and symptomatic trigeminal&#xD;
             neuralgia.&#xD;
&#xD;
          -  Able to provide HIPAA authorization to share prior medical records/imaging.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Life expectancy less than 1 year, co-existing disease or other characteristic that&#xD;
             precludes appropriate diagnosis of a trigeminal autonomic cephalalgia or trigeminal&#xD;
             neuralgia.&#xD;
&#xD;
          -  Active drug or alcohol use or dependence that, in the opinion of the site&#xD;
             investigator, would interfere with adherence to study requirements&#xD;
&#xD;
          -  Inability or unwillingness of subject or legal guardian/representative to give&#xD;
             informed consent.&#xD;
&#xD;
        Inclusion Criteria for Healthy Volunteers:&#xD;
&#xD;
          -  Inclusion criteria is willingness to consent and be of age 18 and older&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mark Burish, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The University of Texas Health Science Center, Houston</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Rebecca Martinez, RN</last_name>
    <phone>713-486-7771</phone>
    <email>nctt.wec@uth.tmc.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Mark J Burish, MD, PhD</last_name>
    <phone>713-486-7771</phone>
  </overall_contact_backup>
  <location>
    <facility>
      <name>The University of Texas Health Science Center at Houston</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rebecca Martinez, RN</last_name>
      <phone>713-486-7771</phone>
      <email>nctt.wec@uth.tmc.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Headache Classification Committee of the International Headache Society (IHS). The International Classification of Headache Disorders, 3rd edition (beta version). Cephalalgia. 2013 Jul;33(9):629-808. doi: 10.1177/0333102413485658.</citation>
    <PMID>23771276</PMID>
  </reference>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>September 15, 2016</study_first_submitted>
  <study_first_submitted_qc>September 19, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 22, 2016</study_first_posted>
  <last_update_submitted>November 6, 2020</last_update_submitted>
  <last_update_submitted_qc>November 6, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 9, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>The University of Texas Health Science Center, Houston</investigator_affiliation>
    <investigator_full_name>Mark J Burish</investigator_full_name>
    <investigator_title>Assistant Professor, Neurosurgery</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Trigeminal Neuralgia</mesh_term>
    <mesh_term>Neuralgia</mesh_term>
    <mesh_term>Cluster Headache</mesh_term>
    <mesh_term>Anencephaly</mesh_term>
    <mesh_term>Trigeminal Autonomic Cephalalgias</mesh_term>
    <mesh_term>Paroxysmal Hemicrania</mesh_term>
    <mesh_term>Headache</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

